Foxx Life Sciences Celebrates Major Expansion
Foxx Life Sciences celebrates two new manufacturing facilities in Londonderry, New Hampshire and Hyderabad, India.
Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications…
BrainStorm Increases Commercial Manufacturing Capacity
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health for three state-of-the-art cleanrooms…
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany. The permit successfully demonstrates for the first time that Premier Quality together with Record Speed WuXi Biologics consistently delivered in China can also be applied in global countries.
Novo Holdings Leads $200M investment in Esco Lifesciences Group
Novo Holdings today announced that it has co-led with Vivo Capital the over-subscribed US$200 million Series A and Crossover round in Esco Lifesciences Group (“Esco”), a leading provider of life sciences tools and services. The financing will enable Esco to strengthen its position through organic and external growth and transformation, as well as invest in China, thus addressing some of the most dynamic market segments and geographies. Other investors include two Asian sovereign wealth funds and Singapore-based global investor, EDBI.
Grand River Aseptic Manufacturing Opens Large-Scale Injectable Fill/Finish Facility, Significantly Increasing Capacity
Grand River Aseptic Manufacturing (“GRAM”), an agile and modern parenteral contract development and manufacturing organization (CDMO), completed its major $60 million expansion project and recently took occupancy.
FDA approves the first targeted therapy to treat a rare mutation in patients with GIST
GISTs arise from specialized nerve cells found in the walls of the gastrointestinal tract. One or more mutations in the DNA of one of these cells may lead to the development of GIST.
Millstone Medical Outsourcing Expands Medical Device Cleanroom
Millstone Medical Outsourcing has officially broken ground on its new 56,385 square foot facility in Fall River, MA. The MA headquarter campus will now hold a total of 124,367 square feet of production space, including its existing 15,000 square feet of class 10,000/ISO7-rated cleanroom space for medical device packaging operations.
Pepscan Doubles GMP Production Capacity to Facilitate Clients’ Growth
Pepscan announced that its GMP production capacity has doubled. Pepscan is an all-in-one partner in peptides, building on 25 years of experience in advancing and applying peptide expertise to facilitate clients in the development and production of peptides.
Sterile Manufacturing Facility Acquisition by Avara Pharmaceutical Services
Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that it has agreed to acquire the largest sterile manufacturing facility for injectable medicines in Canada from a leading global pharmaceutical company, as part of a continuing expansion of its global footprint.
Life Sciences Cleanroom Manufacturing Facility
Ecolab Inc., the global leader in water, hygiene and energy technologies and services, continues to expand its Greensboro campus with construction of a life sciences cleanroom manufacturing facility to support the launch of the company’s Life Sciences solution portfolio in North America.
Compounding Pharmacy Safety violations
In December, the Food and Drug Administration issued a thorough inspection report on PharMEDium’s Tennessee plant that resulted in a pause in pharmaceutical production, until otherwise permitted. PharMEDium, one of the nation’s largest compounding pharmacy companies, is owned by AmerisourceBergen. It supplies medications to about 77% of hospitals nationwide.
